1Stamler J,Vaccaro O,Neaton JD,et al.Diabetes,other risk factors,and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial[J].Diabetes Care,1993,16:434 -444.
2Herlitz J,Malmberg K.How to improve the cardiac prognosis for diabetes.[J].Diebetes Care,1999,22(Suppl 2):89 -96.
3Vittorio P,Jonathan N,Donna K,et al.Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects:Hypertension Genetic Epidemiology Network(HyperGEN) Study[J].Circulation,2001,103 (1):102-107.
5Rocha R,Williams GH.Rationale for the use of aldosterone antagonists in congestive heart failure.Drugs,2002,62(5):723-731
6Hayashi M,Tsutamoto T,Wada A,et al.Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction.Circulation,2003,107(20):2559-2565
7Bauersachs J,Heck M,Fraccarollo D,et al.Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction:role of vascular superoxide anion formation and endothelial nitric oxide synthase expression.J Am Coll Cardiol,2002,39(2):351-358
8Pitt B,Zannad F,Remme WJ,et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure.N Engl J Med,1999,341(10):709-717
9Pitt B,Remme W,Zannad F,et al.Eplerenone,a selective aldosterone blocker,in patients with left ventricular dysfunction after myocardial infarction.N Engl J Med,2003,348(14):1309-1321
10Cicoira M,Zanolla L,Rossi A,et al.Long-term,dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure.J Am Coll Cardiol,2002,40(2):304-310
